Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$26.24 - $39.63 $1.03 Million - $1.56 Million
-39,400 Reduced 10.16%
348,400 $13.7 Million
Q1 2023

May 16, 2023

BUY
$18.67 - $24.56 $789,741 - $1.04 Million
42,300 Added 12.24%
387,800 $9.44 Million
Q4 2022

Feb 14, 2023

SELL
$17.24 - $23.95 $4.7 Million - $6.54 Million
-272,900 Reduced 44.13%
345,500 $7.4 Million
Q3 2022

Nov 14, 2022

SELL
$9.4 - $18.59 $179,540 - $355,069
-19,100 Reduced 3.0%
618,400 $11.1 Million
Q2 2022

Aug 15, 2022

BUY
$9.12 - $18.9 $1.6 Million - $3.31 Million
175,000 Added 37.84%
637,500 $6.13 Million
Q1 2022

May 16, 2022

BUY
$12.15 - $16.83 $1.95 Million - $2.7 Million
160,300 Added 53.04%
462,500 $7.78 Million
Q4 2021

Feb 14, 2022

SELL
$13.83 - $18.78 $5.06 Million - $6.87 Million
-365,600 Reduced 54.75%
302,200 $5.05 Million
Q3 2021

Nov 15, 2021

BUY
$7.07 - $17.5 $3.67 Million - $9.09 Million
519,200 Added 349.39%
667,800 $10.8 Million
Q2 2021

Aug 11, 2021

SELL
$5.69 - $7.17 $1.93 Million - $2.43 Million
-339,000 Reduced 69.52%
148,600 $938,000
Q1 2021

May 17, 2021

BUY
$5.08 - $6.89 $178,816 - $242,528
35,200 Added 7.78%
487,600 $3.01 Million
Q4 2020

Feb 16, 2021

BUY
$5.65 - $7.66 $206,790 - $280,356
36,600 Added 8.8%
452,400 $3.13 Million
Q3 2020

Nov 16, 2020

BUY
$4.01 - $6.29 $1.26 Million - $1.98 Million
314,400 Added 310.06%
415,800 $2.35 Million
Q2 2020

Aug 14, 2020

BUY
$3.06 - $6.6 $101,898 - $219,780
33,300 Added 48.9%
101,400 $517,000
Q1 2020

May 15, 2020

SELL
$2.83 - $8.44 $384,597 - $1.15 Million
-135,900 Reduced 66.62%
68,100 $234,000
Q4 2019

Feb 14, 2020

BUY
$0.93 - $8.58 $189,720 - $1.75 Million
204,000 New
204,000 $1.75 Million

Others Institutions Holding ISEE

About IVERIC bio, Inc.


  • Ticker ISEE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,078,000
  • Description
  • IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...
More about ISEE
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.